![](https://monteverdelaw.com/wp-content/uploads/case-logo/five-prime-therapeutics-inc.jpg)
Five Prime Therapeutics, Inc. (FPRX) relating to its proposed acquisition by Amgen, Inc. Under the terms of the agreement, FPRX shareholders will receive $38.00 in cash per share.
Five Prime Therapeutics, Inc. (FPRX) relating to its proposed acquisition by Amgen, Inc. Under the terms of the agreement, FPRX shareholders will receive $38.00 in cash per share.